Oncology Nursing News
VerifiedOnline/Digital
One of healthcare’s most dynamic professionals needs a dynamic website. The Oncology Nursing News website provides the latest news and clinical insights for oncology nursing professionals, plus live meeting coverage, video interviews, and blog posts from your peers.
Nursing.OncLive.com allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, blogs, and live coverage from major oncology meetings. As we move ahead, we will continually look for new and better ways to get you oncology news as quickly and efficiently as possible. It is an exciting time for cancer research and treatment, and we look forward to Bringing the Oncology Nursing Community Together. Source
Actions
Media Outlet details
| Scope | National, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesFDA Approves Sevabertinib for HER2-Mutant Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a targeted kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. This decision expands the existing indication for sevabertinib.
Advocacy and Self-Care: Emily Beard on Oncology Navigation
In the latest episode of the “Onc Nurse on Call” podcast, co-editors-in-chief Patricia Jakel, MN, RN, AOCN, and Stephanie Desrosiers, DNP, MSN, RN, AOCNS, BMTCN, sat down with Emily M. Beard, BSN, RN, OCN, CBCN, BHCN. As an oncology survivorship navigator at the Winship Cancer Institute at Emory University, Beard shared how she transitions clinical challenges into opportunities for advocacy and personal resilience.
FDA Camizestrant Approval: Nurses Key to New Breast Cancer Paradigm
The US Food and Drug Administration (FDA) granted accelerated approval to the oral selective estrogen receptor degrader (SERD) camizestrant (Etcamah) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adult patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.
How the Emerging MPN Pipeline Will Reshape PV Nursing and Patient Care
In the rapidly evolving landscape of myeloproliferative neoplasms (MPNs), groundbreaking pipeline therapies are poised to redefine the standard of care for patients living with polycythemia vera (PV). Following a recent Oncology Nursing News case-based roundtable discussion, Dana Delaski, MSN, FNP-BC, a hematology nurse practitioner at the University of Mississippi Medical Center, shared clinical insights on how pipeline agents will reshape patient lives and oncology nursing workflows.
Dana Delaski, MSN, FNP-BC
Dana Delaski, MSN, FNP-BC Articles by Dana Delaski, MSN, FNP-BC Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
FDA Approves Iberdomide: A New Oral Paradigm in Multiple Myeloma Care
The Food and Drug Administration (FDA) has granted accelerated approval to the first-in-class cereblon E3 ligase modulator (CELMoD) iberdomide (Zenbexus) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone (IberDd) for adults with relapsed or refractory multiple myeloma (RRMM). Eligible patients must have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent (IMiD).
Oncology Clinicians Must Prioritize Survivorship Lifestyle Discussions
During the 5 to 10 years of survivorship following initial active breast cancer treatment, oncology clinicians have a unique window to influence long-term patient health. Jenni Sheng, M.D., an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine, emphasized in a recent interview that because patients form strong, trusting bonds with their oncology teams during this phase, a provider's guidance on lifestyle modification carries immense weight.
Nursing Protocols for the New Oral RAS Inhibitor Daraxonrasib
The US Food and Drug Administration has approved daraxonrasib (Rasonque), a first-in-class once-daily oral tablet targeting multiple forms of the RAS protein, the key growth driver in most pancreatic adenocarcinomas. Pancreatic adenocarcinoma comprises 90% to 95% of the 67,000 new cases diagnosed annually in the United States, representing a disproportionately high share of cancer deaths due to late detection and limited options.
Thoracic Oncology Advances and Toxicity Management
Rapid therapeutic developments in thoracic oncology, including next-generation EGFR inhibitors, ALK inhibitors, and antibody-drug conjugates (ADCs), have significantly altered the lung cancer treatment landscape. While these therapies offer unprecedented survival benefits, they introduce unique, complex toxicity profiles that require vigilant management.
FDA Approves Camizestrant for ESR1-Mutated Advanced Breast Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to camizestrant (Etcamah, AstraZeneca) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.